Biomarker research continues to pave the way for personalized approaches to managing late-stage non-small cell lung cancer (NSCLC). Understanding your biomarkers may help you and your doctor make more informed decisions about your cancer care.
Late stage is considered Stage IV. In this stage, cancer has spread beyond the lung.